Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Analyst Ratings

• Total Analysts: 1
• Consensus Rating: Strong Sell
• Price Target: $2.00
• Upside: -50.37%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrea Tan Goldman Sachs	Goldman Sachs	Hold → Strong Sell Downgrades $3 → $2	Hold → Strong Sell	Downgrades	$3 → $2	-50.37%	Jun 5, 2024
Vamil Divan Mizuho	Mizuho	Strong Buy Reiterates $26	Strong Buy	Reiterates	$26	+545.16%	Jun 15, 2023
Marc Goodman SVB Leerink	SVB Leerink	Buy Maintains $42 → $10	Buy	Maintains	$42 → $10	+148.14%	Jan 23, 2023
Andrea Tan Goldman Sachs	Goldman Sachs	Strong Buy → Hold Downgrades $8	Strong Buy → Hold	Downgrades	$8	+98.51%	Oct 14, 2022
Yatin Suneja Guggenheim	Guggenheim	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Oct 14, 2022
Jay Olson Oppenheimer	Oppenheimer	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Oct 13, 2022
Andrea Tan Goldman Sachs	Goldman Sachs	Strong Buy Maintains $49 → $81	Strong Buy	Maintains	$49 → $81	+1,909.93%	Sep 23, 2022
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $50 → $60	Strong Buy	Maintains	$50 → $60	+1,388.83%	Sep 6, 2022
Jay Olson Oppenheimer	Oppenheimer	Buy Maintains $75 → $64	Buy	Maintains	$75 → $64	+1,488.09%	May 9, 2022
Ross Weinreb Goldman Sachs	Goldman Sachs	Strong Buy Maintains $69 → $53	Strong Buy	Maintains	$69 → $53	+1,215.14%	Mar 24, 2022
Marc Goodman SVB Leerink	SVB Leerink	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Dec 20, 2021
Vamil Divan Mizuho	Mizuho	Strong Buy Initiates n/a	Strong Buy	Initiates	n/a	n/a	Nov 18, 2021
Ross Weinreb Goldman Sachs	Goldman Sachs	Strong Buy Initiates n/a	Strong Buy	Initiates	n/a	n/a	Apr 21, 2020
Andrew Tsai Jefferies	Jefferies	Strong Buy Initiates n/a	Strong Buy	Initiates	n/a	n/a	Jan 27, 2020
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Initiates n/a	Strong Buy	Initiates	n/a	n/a	Dec 16, 2019